Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash to test redesigned IL-2, CTLA-4 meds
About three years after joining the search for IL-2 and CTLA-4 therapies without all those nasty side effects, Xilio Therapeutics has teed up $95 million to drive its two lead candidates into the clinic.
The Series C round was led by Rock Springs Capital, and should allow the small Waltham, Massachusetts-based biotech to file INDs for XTX101, its anti-CTLA-4 antibody, in Q2 and XTX202, its IL-2 agonist, in Q3.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.